Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. Mangia A, et al. Among authors: mchutchison jg. Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2. Gastroenterology. 2010. PMID: 20621700 Clinical Trial.
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. Urban TJ, et al. Among authors: mchutchison jg. Hepatology. 2010 Dec;52(6):1888-96. doi: 10.1002/hep.23912. Epub 2010 Oct 7. Hepatology. 2010. PMID: 20931559 Free PMC article.
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW. Darling JM, et al. Among authors: mchutchison jg. Hepatology. 2011 Jan;53(1):14-22. doi: 10.1002/hep.24056. Hepatology. 2011. PMID: 21254158 Free PMC article.
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Thompson AJ, et al. Among authors: mchutchison jg. Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10. Hepatology. 2011. PMID: 21274861 Free PMC article. Clinical Trial.
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, Fried M, Afdhal NH, McHutchison JG, Shianna KV, Goldstein DB, Shuldiner AR, Mitchell BD. Howell CD, et al. Among authors: mchutchison jg. J Hepatol. 2012 Mar;56(3):557-63. doi: 10.1016/j.jhep.2011.10.004. Epub 2011 Oct 23. J Hepatol. 2012. PMID: 22027585 Free PMC article.
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Reddy KR, et al. Among authors: mchutchison jg. Hepatology. 2015 Jul;62(1):79-86. doi: 10.1002/hep.27826. Epub 2015 May 9. Hepatology. 2015. PMID: 25846144 Clinical Trial.
394 results